Details of the Drug

General Information of Drug (ID: DMXDU23)

Drug Name

CAEL-101

Indication

Disease Entry	ICD 11	Status	REF
Al amyloidosis	5D00.0	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

References

1	ClinicalTrials.gov (NCT04504825) A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Na?ve Patients With Mayo Stage IIIb AL Amyloidosis. U.S.National Institutes of Health.